^
BIOMARKER:
EGFR L858R
i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR L858R
NSCLC
bevacizumab
Sensitive
:
C2
J Formos Med Assoc - 3wk
EGFR L858R
NSCLC
afatinib
Sensitive
:
C1
EGFR L858R
NSCLC
osimertinib
Sensitive
:
C1
EGFR L858R
NSCLC
dacomitinib
Sensitive
:
C1
EGFR L858R
NSCLC
gefitinib
Sensitive
:
C1
EGFR L858R
NSCLC
erlotinib
Sensitive
:
C1
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive
:
C1
EGFR L858R
NSCLC
icotinib
Sensitive
:
B
EGFR L858R
NSCLC
gefitinib + rivoceranib
Sensitive
:
B
EGFR L858R
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
B
EGFR L858R
LUAD
gefitinib
Sensitive
:
C1
EGFR L858R
LUAD
erlotinib
Resistant
:
B
EGFR L858R
NSCLC
gefitinib + ramucirumab
Sensitive
:
B
EGFR L858R
Lung Non-Small Cell Squamous Cancer
erlotinib
Sensitive
:
C1
EGFR L858R
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive
:
B
EGFR L858R
Thyroid Gland Anaplastic Carcinoma
erlotinib
Sensitive
:
C1
EGFR L858R
LUAD
osimertinib
Sensitive
:
C1
EGFR L858R
NSCLC
osimertinib + ABT 263
Sensitive
:
C2
EGFR L858R
NSCLC
gefitinib
Sensitive
:
C2
EGFR L858R
NSCLC
gefitinib + osimertinib
Sensitive
:
C2
EGFR L858R
NSCLC
anlotinib + icotinib
Sensitive
:
C2
EGFR L858R
NSCLC
JNJ-61186372
Sensitive
:
C2
EGFR L858R
NSCLC
EGF816
Sensitive
:
C2
EGFR L858R
NSCLC
osimertinib + HMPL-504
Sensitive
:
C2
EGFR L858R
NSCLC
bevacizumab + erlotinib
Sensitive
:
C2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our